Results 21 to 30 of about 949 (151)

Perspectives of Indian Gastroenterologists and Hepatologists on Nonalcoholic Fatty Liver Disease Diagnosis and Management: Insights From the Nationwide Web-Based Cross-Sectional DRIVE Survey [PDF]

Interactive Journal of Medical Research
BackgroundNonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), represent an increasing clinical and public health burden in India. Despite their high prevalence, there are limited
Anil Arora, Yogesh Garje, Shagupta Shaikh, Shruti Dharmadhikari, Chintan Khandhedia, Neeraj Markandeywar, Amey Mane, Suyog C Mehta, Ashish Kumar   +8 more
doaj   +2 more sources

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH

Metabolites, 2022
Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology ...
Ryan D. Welch, Cyrielle Billon, McKenna Losby, Gonzalo Bedia-Diaz, Yuanying Fang, Amer Avdagic, Bahaa Elgendy, Thomas P. Burris, Kristine Griffett   +8 more
doaj   +2 more sources

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence

Diabetes, Metabolic Syndrome and Obesity, 2015
Aravind Sosale,1 Banshi Saboo,2 Bhavana Sosale11Diacon Hospital, Bangalore, 2Dia Care (Diabetes Care and Hormone Clinic), Ahmedabad, IndiaAbstract: Diabetes mellitus (DM) is one of the most dreaded metabolic disorders in the world today.
Sosale A, Saboo B, Sosale B
doaj   +1 more source

Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis [PDF]

Clinical and Molecular Hepatology
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a spectrum of pathology involving fatty liver disease that may progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure.
Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz   +4 more
doaj   +2 more sources

Saroglitazar ameliorates monosodium glutamate-induced obesity and associated inflammation in Wistar rats: Plausible role of NLRP3 inflammasome and NF- κB [PDF]

Iranian Journal of Basic Medical Sciences, 2022
Objective(s): Inflammation is the major progenitor of obesity and associated metabolic disorders. The current study investigated the modulatory role of saroglitazar on adipocyte dysfunction and associated inflammation in monosodium glutamate (MSG) obese ...
Sayima Nabi, Uma Bhandari, Syed Haque
doaj   +1 more source

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. [PDF]

Aliment Pharmacol Ther
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Schattenberg JM, Banales JM, Hirschfield G, Trivedi P, Cable EE, McWherter CA, Billin AN, Crittenden DB, Budas G.   +8 more
europepmc   +2 more sources

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients

, 2023
NAFLD is common after liver transplantation (LT) and is associated with an increased metabolic burden. Currently, there is a paucity of investigations into the treatment of post-LT NAFLD.
Deven Parmar, Mohammad Shadab Siddiqui, Mikael Forsgren, Patel, Samarth,, Boyett, Sherry,, Farheen Shaikh, Sherry Boyett, Anh Tuan Bui, Forsgren, Mikael,, Bui, Anh Tuan,, Sanyal, Arun J.,, Siddiqui, Mohammad Shadab,, Vaishali Patel, Arun J. Sanyal, Samarth Patel, Shaikh, Farheen,, Parmar, Deven,, Patel, Vaishali,   +17 more
core   +3 more sources

The Clinical Aspects of Saroglitazar and its Side Effects [PDF]

, 2020
The new substance element has been known as novel antidiabetic drug, eg: saroglitazar. saroglitazar is a medication used to treat type-2 diabetes. saroglitazar was known under the exchange name Lipaglyn, created by Zydus cadila.
Pasula, Sreenivas, Sumathi, Sheelam, Ratna Sai, Vadlamudi Naga, Rao, A. Srinivas, Sreekanth, Mondra, Prasad, Beda Durga   +5 more
core   +1 more source

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

BMC Pharmacology and Toxicology, 2021
Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate ...
Rasoul Akbari, Tahereh Behdarvand, Reza Afarin, Hamid Yaghooti, Mohammad Taha Jalali, Narges Mohammadtaghvaei   +5 more
doaj   +1 more source

Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice

Heliyon, 2023
We evaluated the effects of select herbal extracts (Tinospora cordifolia [TC], Tinospora cordifolia with Piper longum [TC + PL], Withania somnifera [WS], Glycyrrhiza glabra [GG], AYUSH–64 [AY-64], and Saroglitazar [S]) on various parameters in a diet ...
Deepika Kumari, Jyoti Gautam, Vipin Sharma, Sonu Kumar Gupta, Soumalya Sarkar, Pradipta Jana, Vikas Singhal, Prabhakar Babele, Parul Kamboj, Sneh Bajpai, Ruchi Tandon, Yashwant Kumar, Madhu Dikshit   +12 more
doaj   +1 more source